Physician profile
Hedy P Smith
NPI 1255399895
$21,109.35
in general payments reported to CMS, 2019-2025
30 companies · $2,567 in 2025
The $2,567 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $99.00 · 2021: $9,300 · 2022: $172 · 2023: $7,896 · 2024: $829 · 2025: $2,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,975 · Travel and Lodging: $2,514 · Food and Beverage: $2,438 · Honoraria: $300 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,975.00 |
| Travel and Lodging | $2,513.96 |
| Food and Beverage | $2,438.46 |
| Honoraria | $300.00 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $7,444.73 | 2021 | |
| Pfizer INC. | $7,377.56 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $2,067.86 | 2024-2025 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $1,755.00 | 2021 | |
| Incyte Corporation | $493.13 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Chiesi USA, INC. | $324.71 | 2022-2025 | Ferriprox |
| Celgene Corporation | $263.50 | 2023-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $195.13 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $124.13 | 2022-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $112.26 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Servier Pharmaceuticals LLC | $100.57 | 2023-2025 | |
| Glaxosmithkline, LLC. | $93.66 | 2023-2025 | Ojjaara, Shingrix |
| Alexion Pharmaceuticals, INC. | $88.59 | 2024-2025 | Ultomiris |
| Janssen Scientific Affairs, LLC | $74.43 | 2023 | Darzalex |
| Astellas Pharma US INC | $69.99 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $63.04 | 2019-2024 | Darzalex |
| Abbvie INC. | $59.18 | 2024 | |
| Genzyme Corporation | $56.23 | 2022-2024 | |
| Amgen INC. | $50.22 | 2022-2023 | Vectibix, Xgeva, Nplate |
| Sobi, INC | $45.77 | 2022-2023 | |
| Aveo Pharmaceuticals, INC. | $44.52 | 2024 | |
| Caris Mpi, INC. | $34.97 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $29.72 | 2023 | Krazati |
| Pharmaessentia USA Corporation | $25.97 | 2025 | Besremi |
| Kite Pharma, INC. | $22.97 | 2023 | Yescarta |
| Morphosys, US INC. | $21.45 | 2022 | |
| Pharmacosmos Therapeutics INC. | $20.64 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $18.17 | 2025 | Xermelo |
| Puma Biotechnology, INC. | $16.34 | 2025 | |
| Azurity Pharmaceuticals, INC. | $14.91 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hedy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.